Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12508993 | 0.93 | APP (0.60) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL12509569 | 0.89 | DYRK1A (0.57) | APPGLAGAASULT1A1KDM4E | |
| SCHEMBL5429982 | 0.87 | APP (0.83) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL12509332 | 0.86 | APP (0.59) | APPNPC1RAB9A | |
| SCHEMBL1984039 | 0.83 | SULT1A1 (0.72) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL1984042 | 0.83 | SULT1A1 (0.72) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL12509024 | 0.83 | APP (0.55) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL26017584 | 0.83 | APP (0.76) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL12508992 | 0.83 | HDAC6 (0.53) | APPGLAGAASULT1A1KDM4E | |
| SCHEMBL12509012 | 0.82 | APP (0.60) | APPGLAGAASULT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120177572-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-07-12 | — | — | US | disclosed |
| US-20080286202-A1 | Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition | UNIVERSITY OF PITTSBURGH (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177572-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | TTR, APP, SAAL1 | APP 2/4885GLA 48/4885GAA 151/4885 |
| US-20080286202-A1 | Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition | PSEN2, PSEN1, APP | APP 3/4885GLA 57/4885GAA 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.